Israel’s Neurim is conducting a Phase 2 trial of its Piromelatine treatment, for Alzheimer’s disease (AD). The 26-week trial will compare once-daily oral doses of Piromelatine to placebo in approximately 500 patients diagnosed with mild AD.

http://www.neurim.com/news/2016-09-28/neurim-pharmaceuticals-announces-first-patients-enrollments-in-recognition-phase-ii-clinical-trial-of-piromelatine-for-mild-alzheimers-disease/